ArticleTechnical innovations & patient support in radiation oncology2025
Improved PTV coverage and OAR sparing with stereotactic MRI-guided online adaptive radiotherapy with elective fields in pancreatic cancer.
Article in Technical innovations & patient support in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Global hotspots and trends of stereotactic radiotherapy for pancreatic cancer: a bibliometric analysis and visual analysis from 2015 to 2025.Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Ablative stereotactic radiotherapy for pancreatic ductal adenocarcinoma (PDAC) is limited by adjacent radiosensitive organs at risk (OAR) that exhibit significant daily positional variability. This study aims to investigate the benefit of stereotactic MRI-guided online adaptive radiotherapy (SMART) with elective fields on target coverage and OAR dose sparing in patients with PDAC. Methods: We retrospectively analysed 62 consecutive PDAC patients treated with SMART between 2020-2024, totaling 310 fractions. For each fraction, a non-adapted plan (PLAN Results: Prescribed doses were 40 Gy (71 %) and 33 Gy (29 %) over five fractions. A simultaneous integrated boost approach was used in 47 % of patients. The PLAN Conclusion: For the vast majority of PDAC patients treated with stereotactic radiotherapy with elective fields daily online adaptation enhances target coverage and OAR sparing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.